$39.545
-0.819 (-2.07%)At close
THRM News
THRM Events
Board Approves New $400M Stock Repurchase Program
The Board of Directors authorized a new stock repurchase program of up to $400M of the company's issued and outstanding common stock. The new program will replace the company's existing stock repurchase program effective July 27, 2026, and will remain in effect for a three-year period. As of June 30, 2026, the prior program had approximately $110M of stock repurchase authorization remaining.
FY26 Revenue Consensus at $1.56B, Adjusted EBITDA View Raised to $185M-$200M
FY26 revenue consensus $1.56B. Raises FY26 adjusted EBITDA view to $185M-$200M from $175M-$195M; Adjusted free cash flow view to $85M-$100M from $80M-$100M.
Gentherm Reports Q2 Revenue of $416.2M
Reports Q2 revenue $416.2M, consensus $382.87M. "The Gentherm team demonstrated strong commercial performance with record quarterly revenue, while also scaling our core technologies into new markets. Our growth initiatives in both home and office, and medical markets continued to accelerate." said Bill Presley, the Company's President and CEO. "In addition, I was pleased with our execution during the quarter. The operating systems and key performance indicators we have put in place to drive more rigor and standardization throughout the business are yielding positive results."
Gentherm Receives FDA 510 Clearance for ThermAffyx System
Gentherm announced it received FDA 510 clearance for its patented ThermAffyx Patient Safety System. This Class II medical device combines active patient warming, securement and pressure reduction in a platform designed for robotic-assisted surgical procedures. Product trials at healthcare facilities are scheduled to begin in August, with revenue generation expected to commence in Q3.
Gentherm Reports Q1 Revenue of $393.7M, Exceeds Expectations
Reports Q1 revenue $393.7M, consensus $362.23M. "Our team executed well in Q1. We started seeing the tangible results from our efforts to establish a more robust operating system which drove improved performance on stronger volumes. We also continued progressing our organic growth initiatives in both home and office, and medical markets," said Bill Presley, CEO. "This quarter also marked a strategic inflection point for Gentherm. Our announced combination with Modine Performance Technologies creates a stronger enterprise, with an expanded product portfolio, broader end market exposure, and clear value creation opportunities. While we navigate any potential near-team volatility, we are strategically repositioning the company, and I remain confident we have the right plan established to drive improved performance over the long-term."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.